REPLY
Interferon-
in Chronic Hepatitis C
Patrick Marcellin, MD
1 June 1998 | Volume 128 Issue 11 | Page 956
IN RESPONSE:
We believe that in cirrhotic patients, as clearly shown in Bruno and colleagues' observation, a sustained response to interferon-
2a therapy does not eliminate the risk for hepatocellular carcinoma. We agree that these patients, and all cirrhotic patients, should be carefully monitored for early detection of hepatocellular carcinoma. However, we think that in patients without cirrhosis who have a sustained response, the risk for developing cirrhosis and hepatocellular carcinoma is probably extremely low. Of course, further studies on larger populations with a longer follow-up are needed to assess the long-term outcome of patients after interferon- therapy.
|
Author and Article Information
|
|---|
 Top
 Author & Article Info
|
|---|
Hopital Beaujon; Clichy, France
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Article
